These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16581161)

  • 1. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.
    Firbas C; Jilma B; Tauber E; Buerger V; Jelovcan S; Lingnau K; Buschle M; Frisch J; Klade CS
    Vaccine; 2006 May; 24(20):4343-53. PubMed ID: 16581161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
    Klade CS; Wedemeyer H; Berg T; Hinrichsen H; Cholewinska G; Zeuzem S; Blum H; Buschle M; Jelovcan S; Buerger V; Tauber E; Frisch J; Manns MP
    Gastroenterology; 2008 May; 134(5):1385-95. PubMed ID: 18471515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.
    Firbas C; Boehm T; Buerger V; Schuller E; Sabarth N; Jilma B; Klade CS
    Vaccine; 2010 Mar; 28(12):2397-407. PubMed ID: 20060945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.
    Leroux-Roels G; Depla E; Hulstaert F; Tobback L; Dincq S; Desmet J; Desombere I; Maertens G
    Vaccine; 2004 Aug; 22(23-24):3080-6. PubMed ID: 15297058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
    Wedemeyer H; Schuller E; Schlaphoff V; Stauber RE; Wiegand J; Schiefke I; Firbas C; Jilma B; Thursz M; Zeuzem S; Hofmann WP; Hinrichsen H; Tauber E; Manns MP; Klade CS
    Vaccine; 2009 Aug; 27(37):5142-51. PubMed ID: 19559112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.
    Fytili P; Dalekos GN; Schlaphoff V; Suneetha PV; Sarrazin C; Zauner W; Zachou K; Berg T; Manns MP; Klade CS; Cornberg M; Wedemeyer H
    Vaccine; 2008 Jul; 26(31):3818-26. PubMed ID: 18582999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.
    Schlaphoff V; Klade CS; Jilma B; Jelovcan SB; Cornberg M; Tauber E; Manns MP; Wedemeyer H;
    Vaccine; 2007 Sep; 25(37-38):6793-806. PubMed ID: 17686555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus-specific T cell responses against conserved regions in recovered patients.
    Klade CS; Kubitschke A; Stauber RE; Meyer MF; Zinke S; Wiegand J; Zauner W; Aslan N; Lehmann M; Cornberg M; Manns MP; Reisner P; Wedemeyer H
    Vaccine; 2009 May; 27(23):3099-108. PubMed ID: 19428924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
    Rigopoulou EI; Abbott WG; Williams R; Naoumov NV
    Antiviral Res; 2007 Jul; 75(1):36-42. PubMed ID: 17210188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
    Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
    J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific T cell immune response in chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine].
    Xu QH; Zhang XH; Xie DY; Li JG; Chong YT; Yang L; Lu WL; Gao ZL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Dec; 21(4):334-6. PubMed ID: 18322594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles.
    Niu Y; Komatsu N; Komohara Y; Matsueda S; Yutani S; Ishihara Y; Itou M; Yamada A; Itoh K; Shichijo S
    J Med Virol; 2009 Jul; 81(7):1232-40. PubMed ID: 19475615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.
    Ahlenstiel G; Woitas RP; Iwan A; Nattermann J; Feldmann G; Rockstroh JK; Oldenburg J; Kupfer B; Sauerbruch T; Spengler U
    Immunol Invest; 2009; 38(1):1-13. PubMed ID: 19172482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
    Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cellular immune responses of recombinant hepatitis B (rHB) vaccine and HBsAG derived from Hansenula polymorpha cells].
    Hu ZY; He P; Zhang R; Fang X; Zhu FC; Qiu SH; Li HM; Wang H; Liang ZL; Zhuang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jul; 29(7):706-11. PubMed ID: 19031766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.